| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 5 Feb 2025 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday February 13 2025 inter alia; 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter ended on December 31 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended December 31 2024. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 p.m. and concluded at 06.00 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2024. (As Per BSE Announcement Dated on: 13/02/2025) | ||
| Board Meeting | 28 Jan 2025 | 22 Jan 2025 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday January 28 2025 inter alia; 1. To consider approve finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations). 2. To consider approve finalize the proposal of fund raising by way of equity shares through rights issue in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations) as permitted under applicable law subject to such regulatory/statutory approvals as may be required. 3. Any other matter with the permission of chair. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 P.M. and concluded at 03.45 P.M. (As Per BSE Announcement Dated on: 28/01/2025) | ||
| Board Meeting | 24 Jan 2025 | 20 Jan 2025 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 24, 2025, inter alia; 1. To consider, approve, finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). 2. To consider and approve draft notice of Extra -ordinary General Meeting. 3. Any other matter with the permission of chair. The Board Meeting to be held on 24/01/2025 Stands Cancelled. (As per BSE Announcement Dated on 22/01/2025) | ||
| Board Meeting | 14 Nov 2024 | 6 Nov 2024 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter and half year ended on September 30 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter and half year ended September 30 2024. This Intimation is also available on the companys website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com . Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 01.30 p.m. and concluded at 06.15 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on September 30, 2024. (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 3 Sep 2024 | 3 Sep 2024 |
| considered and approved the following: 1) The Notice of the Nineth (9th) Annual general Meeting (AGM) of the Company 2) The 9th AGM is scheduled to be held on Friday, September 27, 2024 at 09.30 A.M. through Video conferencing (VC) / Other Audio-Visual means (OAVM). 3) The Directors Report of the Company together with Report on Corporate Governance, Management Discussion and Analysis Report and other relevant annexures & Schedules thereto for the financial year ended March 31, 2024. 4) Appointment of Shravan A. Gupta & Associates, Practicing Company Secretaries as a scrutinizer for 9th Annual General Meeting. 5) Re-Appointment of Mr. Omkar Herlekar (DIN: 01587154), Director who is liable to retire by rotation and eligible for re-appointment. 6) To close Register of Members and Share Transfer Books of the Company from Thursday 21st September 2024 to Friday 27th September 2024 both days inclusive. | ||
| Board Meeting | 14 Aug 2024 | 6 Aug 2024 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 14 2024 inter alia; 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report from the Statutory Auditor for the quarter ended on June 30 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 01.30 p.m. and concluded at 04.30 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on June 30, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on June 30, 2024. (As Per Bse Announcement Dated on 14.08.2024) | ||
| Board Meeting | 30 May 2024 | 24 May 2024 |
| Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 30 2024 inter alia; 1. To consider approve and take on records Audited financial results of the Company for the quarter and the year ended March 31 2024. 2. To discuss any other matter with the permission of the Chairperson. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 8.00 p.m. and concluded at 10.45 p.m. inter- alia have considered and approved the following: The statement of Audited Financial Results of the Company for the quarter and the financial year ended on March 31, 2024 A copy of the statement of audited Financial Results, Cash Flow statement along with Audited Report submitted by the Statutory Auditors of the Company is attached herewith. (As Per BSE Announcement Dated on 30.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
